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Abstract
We report a systematic review and meta-analysis of research using animal models of che-
motherapy-induced peripheral neuropathy (CIPN). We systematically searched 5 online
databases in September 2012 and updated the search in November 2015 using machine
learning and text mining to reduce the screening for inclusion workload and improve accu-
racy. For each comparison, we calculated a standardised mean difference (SMD) effect
size, and then combined effects in a random-effects meta-analysis. We assessed the
impact of study design factors and reporting of measures to reduce risks of bias. We present
power analyses for the most frequently reported behavioural tests; 337 publications were
included. Most studies (84%) used male animals only. The most frequently reported out-
come measure was evoked limb withdrawal in response to mechanical monofilaments.
There was modest reporting of measures to reduce risks of bias. The number of animals
required to obtain 80% power with a significance level of 0.05 varied substantially across
behavioural tests. In this comprehensive summary of the use of animal models of CIPN, we
have identified areas in which the value of preclinical CIPN studies might be increased.
Using both sexes of animals in the modelling of CIPN, ensuring that outcome measures
align with those most relevant in the clinic, and the animal’s pain contextualised ethology will
likely improve external validity. Measures to reduce risk of bias should be employed to
increase the internal validity of studies. Different outcome measures have different statistical
power, and this can refine our approaches in the modelling of CIPN.
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Author summary
Many frequently used and effective cancer chemotherapies can cause a disabling side
effect that features pain, numbness, tingling, and sensitivity to cold and heat in the
extremities known as chemotherapy-induced peripheral neuropathy (CIPN). There are
currently no effective therapies to treat or prevent this condition, and animal models have
been developed to address this. It is important that experiments using animal models of
CIPN are robust and valid if they are to effectively help patients. We used a systematic
approach to identify all 337 studies that have been published describing the use of animal
models of CIPN. We were able to identify that many studies are imperfect in their experi-
mental design, use only male animals, and assess outcomes with limited relevance to the
human condition. Based on a meta-analysis, we provide guidance to the CIPN animal
modelling community to guide future experiments that may improve their utility and
validity.
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect of many fre-
quently used and effective cancer chemotherapeutic agents and is known to impair daily func-
tion and diminish quality of life [1]. Frequently used chemotherapeutic agents reported to
cause neurotoxic effects include platinum derivatives, taxanes [2], vinca alkaloids, epothilones,
and also newer agents (e.g., thalidomide and bortezomib) [3]. The predominant sensory phe-
notype in patients exposed to oxaliplatin or docetaxel is distal symmetrical sensory loss affect-
ing both upper and lower extremities. Symptoms of sensory disturbance reported by patients
include paraesthesiae, numbness or tingling, and, less frequently, pain and cold allodynia [4].
CIPN can present clinically in 2 distinct forms: acute and chronic. The acute form is a chemo-
therapy dose-related, and often dose-limiting, polyneuropathy, which in many cases resolves
in patients once the chemotherapy ceases. In some patients, this will persist, with other patients
only developing symptoms after treatment has finished. A chronic, often painful, distal sensory
neuropathy is still present in 33% of patients 1 year after completion of treatment [5]. No pre-
ventive or curative disease modifying treatments exist, and therefore there is a pressing need
for more effective treatments [6].
Animal models of CIPN are used to investigate the pathophysiology of CIPN and to test
potential therapies [7]. Frequently, chemotherapeutic agents are administered to induce a sen-
sory neuropathy, and behavioural tests are used to assess induced sensory phenomena, such as
evoked pain, and locomotor activity. Unfortunately, the conventional paradigm for drug
development, in which findings are translated from preclinical animal research to clinical
treatments, has been characterised by a lack of success [8,9]. Metaresearch from preclinical
stroke research suggests that limitations in experimental design, conduct, analysis, and report-
ing—such as failure to carry out blinded assessment of outcome, randomisation and allocation
concealment—may be impeding the development of effective therapies [10–13]. This led to
the development of evidence-based guidelines for scientists [14]. These recommendations
have been highly successful in transforming the reporting of measures to reduce risk of bias in
the preclinical stroke field [15].
We have used a systematic review, in which we systematically identify and appraise all avail-
able evidence relevant to a predefined research question to provide a complete and unbiased
summary of available evidence. We seek to establish the extent to which limited experimental
biases influence the preclinical CIPN literature and to provide evidence to inform tactics to
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increase the scientific validity of this research. Our aim is to provide a systematic overview of
research in the field of in vivo animal modelling of CIPN, with a focus on the reporting of
pain-related behavioural outcome measures, to provide useful information for preclinical
researchers wishing to improve the design of experiments and refine the in vivo modelling of
painful neuropathy.
Results
Identification of publications
Our initial systematic search (September 2012) identified 33,184 unique publications, of which
6,506 were identified as reporting in vivo models of painful neuropathy. This screening stage
took 18 person months; 180 of these publications reported models of CIPN (Fig 1).
In the updated search (November 2015), we identified a further 11,880 publications. Using
machine learning and text mining, we identified 6,108 publications as likely to report models
of neuropathic pain, and 928 of these reported models of CIPN. In a random 10% sample of
screened publications (n = 1,188), the classifier with the best fit—using stochastic gradient
descent—had a screening performance of 97% sensitivity, 67% specificity, and 56% precision.
Further details of the different machine-learning approaches applied are available [16]. Of the
928 studies identified to report animal models of CIPN, 157 met our inclusion criteria.
From both searches, a total of 337 unique publications are included in this review. The rate
of new publications per year is shown in S1 Fig. Metadata from the 337 publications included
in this study are available on the Open Science Framework (OSF; https://doi.org/10.17605/
OSF.IO/ZJEHY). To address concerns that the systematic search is dated we performed a
cumulative meta-analysis, in a post hoc analysis, of the effect sizes and tau2 estimates (an esti-
mate of between-study heterogeneity), ordered by year of publication. It appears that the data
are mature and stable from around 250 studies onwards (S2 Fig).
To investigate sources of heterogeneity we divided the reporting of results by type of study
(i.e., modelling experiments or intervention experiments), and by type of outcome measures
reported (i.e., pain-related behaviours or other behaviours). Therefore, we have 4 datasets: (i)
Data set 1a—modelling of CIPN and reporting pain-related behavioural outcome measures,
(ii) Data set 1b—modelling of CIPN and reporting other behavioural outcome measures, (iii)
Data set 2a –effects of interventions in animal models of CIPN and reporting pain-related
behavioural outcome measures, and (iv) Data set 2b—effects of interventions in animal models
of CIPN and reporting other behavioural outcome measures.
Outcome measures
Across the 337 publications included, we extracted all behavioural outcome measure data.
Pain-related outcome measures included evoked limb withdrawal to stimuli (mechanical, heat,
cold, and/or dynamic mechanical touch), evoked limb withdrawal and/or vocalisation to pres-
sure stimuli, evoked tail withdrawal to stimuli (cold, heat, and/or pressure), and complex
behaviours, e.g., burrowing activity. Other outcome measures included assessment of locomo-
tor function, memory, reward, and attention. Pain-related and other outcome measures for
both modelling and intervention experiments were analysed separately (Fig 2). The full list of
behavioural outcome measures and behavioural tests is given in Tables 1 and 2. The most fre-
quently reported pain-related outcome measure was evoked limb withdrawal to mechanical
stimuli, most frequently assessed using monofilaments (Table 1). The most frequently reported
other behavioural outcome measure was locomotor function, with the rotarod apparatus used
in most cases (Table 2).
Animal models of chemotherapy-induced peripheral neuropathy
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000243 May 20, 2019 3 / 34
Interventions
A total of 306 different interventions were tested (S3 Fig). Most (80%) were only tested in 1
publication, and the most frequently reported interventions were gabapentin, morphine, and
pregabalin, which were reported in 26, 22, and 11 publications, respectively.
Fig 1. Flow diagram of included studies. CIPN, chemotherapy-induced peripheral neuropathy.
https://doi.org/10.1371/journal.pbio.3000243.g001
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Risk of bias
The reporting of measures to reduce risk of bias was ‘moderate’ across included studies
(n = 337): 51.3% (n = 173) reported blinded assessment of outcome, 28.5% (n = 96) reported
randomisation to group, 17.8% (n = 60) reported animal exclusions, 2.1% (n = 7) reported the
use of a sample size calculation, and 1.5% (n = 5) reported allocation concealment.
Across all included studies, 49.6% (n = 167) reported a conflict of interest statement, and
96.7% (n = 326) reported compliance with animal welfare regulations (Table 3).
The methods used to implement randomisation and blinding, and the methods and
assumptions for sample size calculations, were rarely reported: 6 publications reported that
animals were randomly allocated to experimental groups using randomly generated number
sequences, and 2 publications reported that this was done by block randomisation (8.3% of
those that reported randomisation; 8 out of 96). One publication reported that randomisation
was performed by ‘picking animals randomly from a cage’, which we do not consider a valid
method of randomisation [17]. Nine publications reported that blinded outcome assessment
was achieved by using a different experimenter to perform assessments, and 2 publications
reported that a group code was used (6.4% of those that reported blinding; 11 out of 173). One
study reported that allocation concealment was achieved using a coded system (20% of those
that reported allocation concealment; 1 out of 5). Methods of sample size calculation were
reported by 5 publications (71.4% of those that reported a sample size calculation; 5 out of 7): 3
used published or previous results from the group, and 2 had performed a pilot study to
inform sample size calculations.
Modelling experiments
Animal studies modelling CIPN: Pain-related behavioural outcome measures (data set
1a). In modelling experiments using pain-related behavioural outcome measures, adminis-
tration of a chemotherapeutic agent led to increased pain-related behaviour compared to sham
controls (−2.56 standard deviation [SD] [95% CI −2.71 to −2.41], n = 881 comparisons). Spe-
cies did not account for a significant proportion of the heterogeneity, and therefore mouse and
rat experiments were analysed together (mice: −2.63 SD [95% CI −2.86 to −2.39], n = 337
Fig 2. Description and summary of data sets included in this review.
https://doi.org/10.1371/journal.pbio.3000243.g002
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Table 1. Pain-related behavioural outcome measures across intervention and modelling experiments. Numbers
indicate the number of individual comparisons.
Pain-related behavioural outcome Modelling Intervention
Number of comparisons
ELW: Mechanical 534 750
Dynamic plantar aesthesiometer 1 2
Electronic "von Frey" 66 143
Mechanical monofilament 458 593
Normal non-noxious palpation of the tibia 1 0
Pin prick 8 12
Pinch test 2 2
ELW: Cold 191 264
Acetone/ethylchloride/menthol 110 140
Cold plate 73 117
Cold probe 1 0
Cold tolerance 0 1
ELW: cold water 6 6
Limb immersion: cold 1 0
ELW or vocalisation: Pressure 149 240
ELW or vocalisation: pressure 149 240
ELW: Heat 135 146
ELW: radiant heat 101 84
Hot plate 34 61
Paw immersion: heat 0 1
ETW: Cold 43 51
Tail immersion: cold 43 51
ETW: Heat 54 44
Tail flick: heat 33 32
Tail immersion: heat 21 12
Complex behaviour 8 12
AITC-evoked nocifensive behaviour 1 2
Burrowing activity 2 0
Capsaicin-evoked nocifensive behaviour 1 0
Conditioned place preference: pain-related 0 2
Orofacial operant assessment: cold 2 4
Thermal place preference: cold 2 4
ELW: Dynamic mechanical touch 5 4
Rough brush 2 2
Soft brush/cotton tip/ball 3 2
ETW: Pressure 2 0
Tail pressure test 2 0
Frequent descriptions for ELW or vocalisations: pressure (with the Randall-Selitto/paw pressure test). Frequent
description for ELW: radiant heat (with Hargreave’s).
Abbreviations: AITC, TRPA1 agonist allyl isothiocyanate; ELW, evoked limb withdrawal; ETW, evoked tail
withdrawal.
https://doi.org/10.1371/journal.pbio.3000243.t001
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comparisons; rats: −2.52 SD [95% CI −2.71 to −2.32], n = 544 comparisons; Q = 1.16, df = 1,
p = 0.28).
Study design. The type of pain-related outcome measure accounted for a significant pro-
portion of the heterogeneity (Q = 307.27, df = 8, p� 0.01; Fig 3A).
We identified 12 different chemotherapeutic agents used to model CIPN in animals
(Table 4). The chemotherapeutic agent used accounted for a significant proportion of the het-
erogeneity observed (Q = 174.26, df = 11, p< 0.01; Fig 3B). Sex accounted for a significant
proportion of the heterogeneity (Q = 137.11, df = 3, p< 0.01; Fig 4A).
The time to assessment did not account for a significant proportion of heterogeneity (τ2 =
2.55, I2 = 85.98%, p = 0.999).
In a post hoc analysis, we found that the strain of animal accounted for a significant propor-
tion of the heterogeneity (Q = 269.58, df = 22, p< 0.01; Fig 4B). The most frequently reported
strain was Sprague Dawley rats (−2.43 SD [95% CI −2.61 to −2.26], n = 437 comparisons).
Statistical power of different outcome measures. The number of animals required to
achieve 80% power with a significance level of 0.05 varied substantially across the behavioural
tests. For the most frequently reported behavioural tests—mechanical monofilaments, Ran-
dall-Selitto paw pressure test, electronic ‘von Frey’, acetone test/ethyl chloride spray, cold
plate, and Plantar Test (Hargreave’s method)—we calculated the number of animals required
in model and sham groups.
When both standardised mean difference (SMD) effect sizes and pooled SD were at the
50th percentile, the number of animals required ranged from 5 (electronic ‘von Frey’) to 75
per group (Randall-Sellito paw pressure test) (Fig 5). With an effect size at the 20th percentile
and a variance at the 50th percentile, the number of animals required ranged from 13 (elec-
tronic ‘von Frey’) to 297 (Randall-Selitto paw pressure test) (Fig 5), demonstrating that some
Table 2. Other behavioural outcome measures across intervention and modelling experiments. Number of indi-
vidual comparisons.
Other behavioural outcome Modelling Intervention
Number of comparisons
Locomotor function 73 37
Rotarod: locomotor function 34 23
Grip test: motor strength 14 1
Locomotor activity 10 6
Open field: distance travelled 4 0
Open field: exploratory behaviour 2 2
Open field: loading on hind limbs 2 2
Open field: immobility 2 0
Open field: locomotor activity 2 0
Catwalk: gait alterations 2 0
Balance beam: motor coordination 1 1
Cannabinoid tetrad test 0 1
Cannabinoid tetrad test: motility 0 1
Memory 8 0
Novel location preference: preference score 4 0
Novel object preference: preference score 4 0
Reward 4 6
Conditioned place preference: rewarding effects 4 6
Attention 3 0
Prepulse inhibition: attention 3 0
https://doi.org/10.1371/journal.pbio.3000243.t002
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behavioural tests have less sensitivity to detect small effect sizes. The values for the 20th, 50th,
and 80th percentiles of SMD effect sizes and SDs for each behavioural test are available on the
OSF (https://doi.org/10.17605/OSF.IO/ZJEHY).
Risk of bias. Reporting of blinded assessment of outcome (Q = 33.62, df = 1, p< 0.007)
and animal exclusions (Q = 28.99, df = 1, p< 0.007) accounted for a significant proportion of
Table 3. Reporting of measures to reduce the risk of bias and reporting.
Risk of bias Reporting
Blinded assessment
of outcome
Allocation
concealment
Random
allocation to
group
Sample size
calculation
Animal
exclusions
Conflict of
interest statement
Compliance with animal
welfare regulations
% Reporting
(Number/337)
51.3
(173)
1.5
(5)
28.5
(96)
2.1
(7)
17.8
(60)
49.6
(167)
96.7
(326)
https://doi.org/10.1371/journal.pbio.3000243.t003
Fig 3. Impact of study design in modelling experiments using pain-related behavioural outcomes (data set 1a). The size of the
squares represents the number of nested comparisons that contribute to that data point and the value N represents the number of
animals that contribute to that data point. (A) Outcome measure accounted for a significant proportion of the heterogeneity. ETW,
ELW, and complex behaviours used to measure pain. (B) Chemotherapeutic agent accounted for a significant proportion of the
heterogeneity. ELW, evoked limb withdrawal; ETW, evoked tail withdrawal; SMD, standardised mean difference.
https://doi.org/10.1371/journal.pbio.3000243.g003
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the observed heterogeneity, although effect sizes for blinding are very similar between strata
(in which strata refers to the subgroups of comparisons, i.e., blinded versus not blinded).
Reporting of randomisation, allocation concealment, and sample size calculation did not
account for a significant proportion of the observed heterogeneity (Fig 6); data table available
on the OSF (https://doi.org/10.17605/OSF.IO/ZJEHY).
Table 4. Model details including chemotherapeutic agents, route of administration, median cumulative dose, and upper and lower quartiles (data set 1a).
Animal Type Chemotherapeutic agent Route of administration Median Q1 Q3
Mouse Hydroxamate histone deacetylase inhibitors JNJ-26481585 Subcutaneous 32.5 23.75 41.25
Other Salinomycin Intraperitoneal 140 140 140
Platinum compounds Cisplatin Hindpaw 0.004 0.002 0.022
Intraperitoneal 20.5 8.25 23
Subcutaneous 0.15 0.15 0.15
Oxaliplatin Hindpaw 0.04 0.04 0.04
Intraperitoneal 10 3 30
Intravenous 23 13.5 31
Subcutaneous 0.04 0.04 0.04
Proteasome inhibitors Bortezomib Intraperitoneal 0.75 0.425 1.95
Intravenous 6.4 6.4 6.4
Subcutaneous 12 12 18
Taxanes Paclitaxel Intraperitoneal 10 5 16
Intravenous 190 165 230
Subcutaneous 10 10 10
Tail vein 75 75 75
Vinca alkaloids Vincristine Intraperitoneal 0.7 0.2 3.9
Rat Binding of growth factor inhibitors Suramin Intravenous 25 17.5 37.5
Other Methotrexate Subcutaneous 3.75 3.75 3.75
Platinum compounds Carboplatin Intraperitoneal 112.5 101.25 123.75
Cisplatin Intraperitoneal 10 5 15
Intravenous 2 2 2
Subcutaneous 8 8 8
Oxaliplatin Intraperitoneal 16 8 32
Intravenous 2 2 8
Proteasome inhibitors Bortezomib Intraperitoneal 0.7 0.6 1
Intravenous 4.8 4.2 4.8
Taxanes Docetaxel Intravenous 25 17.5 32.5
Tail vein 10 10 10
Paclitaxel Intraperitoneal 8 7.25 8.5
Intravenous 24.5 9.75 33.25
Tail vein 8 8 8
Intrathecala 6 3.1 13
Nanoparticle albumin-bound paclitaxel Intravenous 26.8 25.4 28.2
Vinca alkaloids Vincristine Intraperitoneal 0.95 0.5 1
Intravenous 0.435 0.2125 0.75
Subcutaneous 0.42 0.42 0.42
Tail 0.625 0.5625 0.6875
a Drug doses are shown in mg/kg, except intrathecal paclitaxel, shown in ng.
https://doi.org/10.1371/journal.pbio.3000243.t004
Animal models of chemotherapy-induced peripheral neuropathy
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000243 May 20, 2019 9 / 34
Compliance with animal welfare regulations accounted for a significant proportion of
observed heterogeneity (Q = 19.44, df = 1, p< 0.007), although effect sizes are very similar
between strata (Fig 7). Reporting of a conflict of interest statement did not account for a signif-
icant proportion of the heterogeneity (Fig 7).
Fig 4. Impact of study design in modelling experiments using pain-related behavioural outcomes (data set 1a). The size of the
squares represents the number of nested comparisons that contribute to that data point, and the value N represents the number of
animals that contribute to that data point. (A) Sex accounted for a significant proportion of the heterogeneity. (B) Strain accounted
for a significant proportion of the heterogeneity. SMD, standardised mean difference.
https://doi.org/10.1371/journal.pbio.3000243.g004
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Publication bias. There were 1,123 individual comparisons (−2.58 SD [95% CI −2.72 to
−2.45]). Visual inspection of funnel plots indicated asymmetry, suggesting missing studies (Fig
8A). Trim and fill analysis imputed 316 theoretical missing studies on the right-hand side of
the funnel plot (Fig 8B). Inclusion of these theoretical missing studies decreased the estimate
of modelling-induced pain-related behaviour by 30% to −1.82 SD (95% CI −1.97 to −1.68).
Furthermore, Egger’s regression line and 95% CIs did not pass through the origin
(p = 6.85 × 10−7), consistent with small study effects and again consistent with publication bias
(Fig 8C).
Animal studies modelling CIPN: Other behavioural outcomes (data set 1b)
In addition, as a secondary outcome, we abstracted data from modelling experiments using
other behavioural outcomes (locomotor function, memory, reward behaviours, and attention).
Administration of chemotherapeutic agents led to increased pain-related behaviours com-
pared to sham controls (−0.75 [95% CI −1.04 to −0.47], n = 63 comparisons). Species did not
account for a significant proportion of the heterogeneity (Q = 3.29, df = 1, p = 0.070), and
therefore rats and mice were analysed together.
Study design. Type of outcome measure accounted for a significant proportion of the het-
erogeneity (Q = 25.44, df = 3, p< 0.01; all figures related to data set 1b are available in S4A
Fig).
Chemotherapeutic agent accounted for a significant proportion of the heterogeneity
(Q = 28.90, df = 7, p< 0.01; S4B Fig).
Fig 5. Power analysis for modelling experiments (data set 1a). Number of animals required per group to obtain 80% power with a
significance level of 0.05 using mechanical monofilaments, Randall-Selitto paw pressure test, electronic ‘von Frey’, acetone test/ethyl
chloride spray, cold plate, and Hargreave’s. Effect sizes calculated by SMD. SMD, standardised mean difference.
https://doi.org/10.1371/journal.pbio.3000243.g005
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Sex (Q = 3.29, df = 1, p = 0.70) and time to assessment (τ2 = 0.63, I2 = 73.45%, p = 0.05) did
not account for a significant proportion of the heterogeneity in modelling experiments using
other behavioural outcomes.
A post hoc analysis found that strain accounted for a significant proportion of the heteroge-
neity (Q = 23.98, df = 6, p< 0.01; S4C Fig).
Risk of bias. Reporting of randomisation, blinding, allocation concealment, sample size
calculation, or animal exclusions did not account for significant proportions of the heteroge-
neity (S5 Fig) nor did reporting of compliance with animal welfare regulations or a conflict of
interest statement (S6 Fig).
Publication bias. There were 88 individual comparisons (−0.71 SD [95% CI −0.96 to −-
0.47]). Visual inspection of funnel plots indicated asymmetry, suggesting missing studies (S7A
Fig). Trim and fill analysis imputed 21 theoretical missing studies on the right-hand side of the
funnel plot (S7B Fig). Inclusion of these theoretical missing studies decreased the estimate of
modelling-induced pain-related behaviour by 56% to −0.31 SD (95% CI −0.58 to −0.05). How-
ever, Egger’s regression was not consistent with small study effects (p = 0.293) (S7C Fig).
Intervention experiments
Drug interventions in animal models of CIPN: Pain-related behavioural outcome mea-
sures (Data set 2a). In CIPN intervention studies using pain-related behavioural outcome
measures, administration of an intervention led to a 1.53 SD (95% CI 1.45–1.61) attenuation
of pain-related behaviour compared to control (n = 1,360 comparisons, p< 0.007). Species did
not account for a significant proportion of the heterogeneity (Q = 4.57, df = 1, p = 0.03), and
so mouse and rat experiments were analysed together.
Study design. The type of intervention accounted for a significant proportion of the het-
erogeneity (Q = 1,418.27, df = 304, p< 0.007). The most frequently tested interventions were
Fig 6. Effect sizes associated with measures to reduce risk of bias in modelling experiments using pain-related behavioural
outcomes (data set 1a).
https://doi.org/10.1371/journal.pbio.3000243.g006
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morphine (n = 53 comparisons), gabapentin (n = 51 comparisons), and pregabalin (n = 35
comparisons) (Fig 9). No clear dose-response relationship was observed for any of these drugs,
investigated by calculating the cumulative dose.
The type of pain-related outcome measure accounted for a significant proportion of the
heterogeneity (Q = 24.36, df = 7, p< 0.007; Fig 10A).
In intervention studies, the chemotherapeutic agent used to induce the pain model
accounted for a significant proportion of the heterogeneity (Q = 22.51, df = 6, p< 0.007; Fig
10B). The most frequently reported chemotherapeutic agents were paclitaxel (n = 520) and
oxaliplatin (n = 480).
Sex of animal did not account for a significant proportion of the heterogeneity (Q = 3.27,
df = 3, p = 0.35).
Time to assessment accounted for a significant proportion of the heterogeneity, with a lon-
ger interval associated with greater attenuation of pain-related behaviour (p< 0.007; Fig 10C).
However, time of intervention administration did not account for a significant proportion of
the heterogeneity (τ2 = 0.81, I2 = 57.51%, p = 0.5776).
In a post hoc analysis, we found that the strain of animal accounted for a significant propor-
tion of the heterogeneity (Q = 120.25, df = 19, p< 0.007; Fig 10D). The most frequently
reported were Sprague Dawley rats (n = 759).
Ranking drug efficacy. We performed a post hoc analysis in which we compared the
ranking of drugs common between a clinical systematic review [18] and our review. A
Fig 7. Effect sizes associated with reporting of compliance with animal welfare regulations and a statement of potential conflict
of interests in modelling experiments using pain-related behavioural outcomes (data set 1a).
https://doi.org/10.1371/journal.pbio.3000243.g007
Animal models of chemotherapy-induced peripheral neuropathy
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000243 May 20, 2019 13 / 34
Spearman’s rank correlation coefficient found no correlation between clinical and preclinical
rank (rs = −0.0099, p = 0.9699; Fig 11).
Statistical power of different outcome measures. In intervention studies, the number of
animals required to obtain 80% power with a significance level of 0.05 varied substantially
across pain-related behavioural tests. For mechanical monofilaments, Randall-Selitto paw
pressure test, electronic ‘von Frey’, acetone test/ethyl chloride spray, cold plate, and Plantar
Test (Hargreave’s method), we calculated the number of animals required in intervention and
control groups.
When both the SMD effect size and pooled SD were the 50% percentile, the number of ani-
mals required ranged from 8 (acetone test/ethyl chloride spray) to 242 (Randall-Selitto paw
pressure test) (Fig 12). With an effect size at the 20th percentile and a variance at the 50th per-
centile, the number of animals required increased substantially, ranging from 46 (Hargreave’s)
to 1,315 (Randall-Selitto paw pressure test). This again demonstrates that some behavioural
tests have less sensitivity to detect small effect sizes. The values for the 20th, 50th, and 80th
Fig 8. Assessment of publication bias in modelling experiments in which a pain-related outcome was used (data set 1a). (A)
Visual inspection of the funnel plot suggests asymmetry. Filled circles represent reported experiments. Solid line represents global
effect size, and dashed line represents adjusted global effect size. (B) Trim and fill analysis imputed theoretical missing studies
(unfilled circles). Filled circles represent reported experiments. Solid line represents global effect size, and dashed line represents
adjusted global effect size. (C) Egger’s regression indicated small study effects.
https://doi.org/10.1371/journal.pbio.3000243.g008
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percentile of mean differences and pooled SDs for each behavioural test are provided on the
OSF (https://doi.org/10.17605/OSF.IO/ZJEHY).
Risk of bias. Reporting of allocation concealment, animal exclusions, and sample size cal-
culations accounted for a significant proportion of the heterogeneity (Fig 13; data table avail-
able on the OSF; https://doi.org/10.17605/OSF.IO/ZJEHY), with studies that did not report
Fig 9. Intervention accounted for a significant proportion of the heterogeneity in intervention experiments using pain-related
behavioural outcomes (data set 2a). Plot shows interventions with 10 or more comparisons. The size of the squares represents the
number of nested comparisons that contribute to that data point, and the value N represents the number of animals that contribute
to that data point.
https://doi.org/10.1371/journal.pbio.3000243.g009
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these items giving greater estimates of effect. Reporting of randomisation and blinded assess-
ment of outcome did not account for a significant proportion of the heterogeneity.
Both reporting of compliance with animal welfare regulations (Q = 8.86, df = 1, p< 0.007)
and reporting of a conflict of interest statement (Q = 8.28, df = 1, p< 0.007) accounted for a
significant proportion of the heterogeneity (Fig 14). Failure to report this information was
associated with smaller estimates of effect.
Fig 10. Impact of study design in intervention experiments using pain-related behavioural outcomes (data set 2a). The size of
the squares represents the number of nested comparisons that contribute to that data point, and the value N represents the number
of animals that contribute to that data point. (A) Outcome measure accounted for a significant proportion of the heterogeneity. (B)
Chemotherapeutic agent accounted for a significant proportion of the heterogeneity. (C) Time of assessment accounted for a
significant proportion of the heterogeneity. (D) Strain accounted for a significant proportion of the heterogeneity.
https://doi.org/10.1371/journal.pbio.3000243.g010
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Publication bias. There were 1,513 individual comparisons (1.52 SD [95% CI 1.44–1.59]).
Visual inspection of funnel plots indicated asymmetry, suggesting missing studies (Fig 15A).
Trim and fill analysis imputed 389 theoretical missing studies on the left-hand side of the fun-
nel plot (Fig 15B). The inclusion of these theoretical missing studies decreased the estimate of
intervention effects by 28% to 1.09 SD (95% CI 1.01–1.16). Furthermore, Egger’s regression
was consistent with small study effects (p = 2.17 × 10−6), suggesting funnel plot asymmetry
(Fig 15C).
Drug interventions in animal models of CIPN: Other behavioural
outcomes (data set 2b)
In intervention studies using other behavioural outcomes, administration of interventions led
to improvement in other behaviours compared to controls (0.69 SD [95% CI 0.37–1.0], n = 37
comparisons). Species did not account for a significant proportion of the heterogeneity
(Q = 0.75, df = 1, p = 0.39).
Study design. Two outcome measures were used, and this accounted for a significant pro-
portion of the heterogeneity. We observed greater improvement in reward-related behaviours
compared with locomotor function (1.61 SD [95% CI 1.13–2.09], n = 6) comparisons versus
(0.52 [95% CI 0.20–0.85], n = 31 comparisons [Q = 13.70, df = 1, p< 0.007]; S8A Fig).
The type of intervention accounted for a significant proportion of the heterogeneity
(Q = 51.82, df = 19, p< 0.007; S9 Fig).
Fig 11. Rank order of clinical and preclinical drugs (data set 2a). A Spearman’s correlation was run to assess the relationship
between clinical and preclinical rank of 17 drugs. There was no correlation between clinical and preclinical rank; rs = −0.0099,
p = 0.9699.
https://doi.org/10.1371/journal.pbio.3000243.g011
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Chemotherapeutic agent (Q = 2.21, df = 1, p = 0.137), sex (Q = 9.67, df = 2, p = 0.008), time
to assessment (τ2 = 0.37, I2 = 54.21%, p = 0.398), and time of intervention administration (τ2 =
0.32, I2 = 52.37%, p = 0.331) did not account for a significant proportion of the heterogeneity.
In a post hoc analysis, we found that strain accounted for a significant proportion of the
heterogeneity (Q = 16.18, df = 3, p< 0.007; S8B Fig).
Risk of bias. Blinded assessment of outcome accounted for a significant proportion of the
heterogeneity (Q = 8.11, df = 1, p< 0.007) (S10 Fig). Reporting of randomisation or animal
exclusions did not account for a significant proportion of the heterogeneity. No studies in this
data set reported allocation concealment or the use of a sample size calculation. Reporting of a
conflict of interest statement did not account for a significant proportion of the heterogeneity
(S11 Fig). All studies in this data set reported compliance with animal welfare regulations.
Publication bias. There were 43 individual comparisons (0.70 SD [95% CI 0.41–0.99]).
Visual inspection of funnel plots did not indicate asymmetry, suggesting no missing studies.
Trim and fill analysis estimated no theoretical missing studies. Furthermore, Egger’s
regression was not consistent with small study effects (p = 0.352), suggesting funnel plot
symmetry.
Animal husbandry
The reporting of details of animal husbandry was low across all included studies (S1 Table).
No study reported whether different species were housed in the same room.
Fig 12. Power analysis for intervention experiments. Number of animals required to obtain 80% power with a significance level of
0.05 using mechanical monofilaments, Randall-Selitto paw pressure test, electronic ‘von Frey’, acetone test/ethyl chloride spray, cold
plate, and Hargreave’s (data set 2a). Effect sizes calculated by SMD. SMD, standardised mean difference.
https://doi.org/10.1371/journal.pbio.3000243.g012
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Fig 13. Effect sizes associated with measures to reduce risk of bias in intervention experiments using pain-related behavioural
outcomes (data set 2a).
https://doi.org/10.1371/journal.pbio.3000243.g013
Fig 14. Effect sizes associated with reporting of compliance with animal welfare regulations and a statement of potential
conflict of interests in intervention experiments using pain-related behavioural outcomes (data set 2a).
https://doi.org/10.1371/journal.pbio.3000243.g014
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Discussion
Our systematic review and meta-analysis includes data from 337 publications describing ani-
mal models of CIPN. We demonstrate in modelling experiments that administration of a che-
motherapeutic agent compared with sham controls leads to an increase in pain-related
behaviours, and in intervention studies, drug administration attenuates pain-related
behaviours.
Animal models of CIPN are used to elucidate the pathophysiology of the condition and to
develop potential therapies. Our purpose here was to synthesise and summarise the entirety of
the animal model CIPN literature primarily to make it accessible to scientists interested in the
field and to provide them with data from which they can efficiently select optimal models to
suit their experimental aims and to plan their experiments to a high level of rigour (e.g., suit-
ably informed sample size calculations).
Here, we show—in 2 cohorts of primary studies, those modelling CIPN compared to sham
controls and those testing the effect of intervention in animal models of CIPN—that there are
some limitations in their experimental design. Our primary focus was on pain-related behav-
iours. Most studies used only male animals (84%) and evoked limb withdrawal to mechanical
Fig 15. Intervention experiments in which a pain-related outcome was used (data set 2a). (A) Visual inspection of the funnel plot
suggests asymmetry. Filled circles represent reported experiments. Solid line represents global effect size, and dashed line represents
adjusted global effect size. (B) Trim and fill analysis imputed theoretical missing studies (unfilled circles). Filled circles represent
reported experiments. Solid line represents global effect size, and dashed line represents adjusted global effect size. (C) Egger’s
regression indicated small study effects. vN, square root of N.
https://doi.org/10.1371/journal.pbio.3000243.g015
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stimuli. Reporting of measures to reduce risk of bias was moderate. Our indicative power cal-
culations allow the ranking of the most commonly reported pain-related behavioural tests and
suggest that the Randall-Sellito paw pressure test may be the least sensitive to detect small
effect sizes. Our analyses also indicate likely publication bias and estimate an average of a 30%
relative overestimation on reported results. This empirical evidence and our suggestions may
generate discussion to guide the design of future studies and the importance of disseminating
experimental findings irrespective of their direction of effect.
In undertaking this review, we observed increasing rates of publications describing primary
studies of animal models of CIPN and that the accrual rate of relevant publications increased
by 89% in 3 years. This presents technical challenges in synthesising a large data set in a timely
manner. We were able to demonstrate the feasibility of using machine learning to facilitate
screening for inclusion in systematic reviews of preclinical studies.
External validity of studies using animal models of CIPN
Misalignment between animal models and the clinical population. Most identified
studies (285 out of 341 [84%]) used only male animals to model CIPN. In the clinic, the che-
motherapeutic agents included in this analysis are frequently used to treat female cancer
patients (e.g., ovarian or breast carcinoma), thus reducing the generalisability of the findings
from these models to the clinical population. Sex only accounted for a significant proportion
of the heterogeneity in the modelling of painful neuropathy in which pain-related behaviours
were measured. It is likely that the paucity of female animals limits our ability to ascertain with
sufficient power the impact of sex on models of CIPN in other contexts. Karp and colleagues
have demonstrated that a large number of mammalian phenotypic traits are sexually dimor-
phic [19], and in line with National Institutes of Health policy [20], we advocate for the use of
female animals in addition to males.
We also have concerns about the clinical relevance of the time courses frequently studied in
animals. Acute CIPN is estimated to affect 68% of patients within the first month of chemother-
apy cessation, 60% at 3 months, and 30% of patients at 6 months [5]. However, chronic CIPN
has been observed in four-fifths of patients exposed to taxane [21] or oxaliplatin [22] approxi-
mately 2 years after treatment. A long-term study showed that oxaliplatin treatment was associ-
ated with CIPN at 6-year follow-up [23]. Therefore, the short duration of these models of CIPN
identified in this systematic review likely model the acute phase. Of those publications in which
study duration (the time between the first administration of chemotherapeutic agent and the
time when animals were euthanised) was reported (39 of 341 publications), the median dura-
tion was only 21 days (16–28 IQR). Furthermore, the median time to outcome assessment in
our modelling data set (the time in which there was the biggest difference between CIPN model
and sham animals) was 14 days (7–25 IQR). The median time to outcome assessment in our
intervention data set was also 14 days (7–22 IQR), indicating that the time in which the drug
interventions are most effective is when the models show the largest modelling effect.
Misalignment between preclinical and clinical outcome measures. The most frequent
behaviours reported in animal models of CIPN are manifestations of gain in sensory function;
hypersensitivity in paw withdrawal evoked by mechanical stimuli was the assay most often
employed. A review of studies reporting preclinical models of pain published in the journal
Pain between 2000 and 2004 also found that the most frequently reported pain-related behav-
iours were such reflex withdrawal responses [24]. This contrasts with chronic CIPN in clinical
practice, in which the predominant clinical sensory phenotype of these patients is one of sen-
sory loss [4,25], and this may compromise the clinical relevance of these models for chronic
CIPN; however, they may have more relevance to acute CIPN.
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One approach to addressing this misalignment between outcome measures used to assess
pain in patients in clinical trials and those frequently reported in animal models of CIPN
would be the development of sensory profiling for rodent models of neuropathy that better
reflect the clinical picture [25].
Internal validity of studies using animal models of CIPN
There was moderate reporting of measures to reduce risk of bias. Our subgroup analyses did
not consistently identify that the reporting of these measures had an impact on experimental
findings. It may be that there was insufficient power to test for these associations because of
the small number of studies reporting these factors or that there is indeed no association. We
also are only able to test the reporting of these measures to reduce risk of bias, and these may
differ according to the actual use of these measures in the design, conduct, and analysis of a
study. The details of methods used to implement randomisation and blinding and the methods
and assumptions for sample size calculation were rarely reported. Despite the inconsistency of
our findings, there is substantial empirical evidence of numerous research domains that these
details are important to understand the validity of the procedures used [17], noting that one of
the included studies reported that randomisation was achieved by selecting animals at random
from the cage. If methods and assumptions were reported, this would allow assessment of the
quality of these procedures that report using tools such as those used in clinical systematic
reviews [26] and allow for more robust assessments of their impact on research findings.
Statistical modelling and meta-analysis have demonstrated that the exclusion of animals
can distort true effects; even random loss of samples decreased statistical power, but if the
exclusion is not random, this can dramatically increase the probability of false positive results
[27]. It has been shown in other research fields that treatment efficacy is lower in studies that
report measures to reduce risk of bias [13,28–30].
Publication bias
Our assessment of publication bias finds evidence to suggest that global effect sizes are sub-
stantially overstated in all data sets except the smallest (and this is likely due to reduced power
to detect publication bias with only 37 studies). We observed relative overstatements in effect
sizes that ranged from 28% to 56%. Publication bias is a prevailing problem in preclinical
research, in which neutral or negative studies are less likely to be published than positive stud-
ies [31]. One potential reason for this is the high competition for academic promotion and
funding, and few incentives to publish findings from studies in which the null hypothesis was
not disproved. Initiatives such as Registered Reports provide one mechanism to support the
publication of well-designed, thoroughly executed, and well-reported studies asking important
questions regardless of the results.
Optimising experimental design
Experimental design of in vivo CIPN studies could be optimised by adopting measures to
reduce risk of bias, such as using sample size calculations to ensure that experiments are appro-
priately powered. It is also important to use a model that best represents the clinical population
of interest, for example, using both female and male animals. To help further address the issue
of publication bias, we suggest that researchers make available prespecified protocols for con-
firmatory preclinical studies and publish all results. Others have shown that external validity
may be increased by using multicentre studies to create more heterogeneous study samples,
for example, by introducing variations in the animal genetics and environmental conditions
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(housing and husbandry) between laboratories, an approach that may be useful in pain
modelling.
One approach that would help optimise experimental design is to use the Experimental
Design Assistant (EDA; https://eda.nc3rs.org.uk/), a free resource developed by the NC3Rs,
whereby researchers create a record of their experimental design [32]. The output from the
EDA could then be uploaded to the OSF as a record for transparency.
Reduction
There are opportunities to reduce waste and maximise the information gained from in vivo
models of pain studies. This would require open and transparent reporting of results. For
example, for complex behaviours, the online dissemination of individual animal video files
[33] would allow reanalysis for further behaviours not reported in the original publication. It is
interesting to note that although the open field was used in studies included in this systematic
review, none of the included studies reported thigmotaxis, an outcome measure reported in
other preclinical pain research. Sharing open field video files would allow this outcome to be
assessed from previously conducted experiments. Our exemplar power calculations of the
most frequently reported behavioural outcome measures highlight the substantial variability in
the statistical performance of different outcome measures. Using these results, it is possible to
rank the different pain-related behavioural tests according to how many animals are required
per group as effect size or SD increases or decreases. This allows researchers to evaluate the
sensitivity of their estimates of numbers required compared with variations in the effect sizes
or variance achieved. Along with other factors, such as clinical relevance, these results can
inform the choice of outcome measure in study design by allowing researchers to select out-
come measures that require fewer animals.
The results of our systematic review show increasing rates of publications of experiments
using animal models of CIPN. Between the initial search in 2012 and the updated search in
2015, the number of relevant publications increased by 89%. The high publication accrual rate
is not unique to this field but is the case across clinical [34] and preclinical research; this makes
it challenging for researchers and consumers of research to keep up to date with the literature
in their field. This systematic review of preclinical models of pain uses machine learning and
text mining and demonstrates the usefulness of these automation tools in this field.
Limitations
Conducting a systematic review is time and resource intensive, and the rate of publication of
new primary research means that systematic reviews rapidly become outdated. This review is
limited because the most recent information included was identified in November 2015. We
plan that the present systematic review form a ‘baseline’ systematic review, which can be
updated and developed into a living systematic review, i.e., one that is continually updated as
new evidence is published [35]. An important secondary output of this review is the advances
made in the use of machine learning to facilitate the automation of systematic reviews of pre-
clinical studies. As new online platforms and tools for machine learning and automation
become available, preclinical living systematic reviews become more feasible [36]. Guidelines
for living systematic reviews [36] and the use of automation tools [37] have recently been pub-
lished, and Cochrane has also launched pilot living systematic reviews [38,39].
The machine-learning algorithm based on our initial screening had a high sensitivity (97%)
and medium specificity (67%). High sensitivity has a low risk of missing relevant literature. An
algorithm with lower specificity is more likely to falsely identify studies for inclusion (i.e., false
positives). As a result, during data abstraction, the 2 independent human screeners excluded
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many studies identified by the machine for inclusion. We believe that this balance between
sensitivity and specificity was appropriate because this reduced the risk of missing relevant
studies.
A further possible limitation of our study is that we chose to extract behavioural data at the
time point at which there was the largest difference between model and sham control animals
or treatment and control animals. This time point was chosen to capture information on inter-
vention effects regardless of their half-life. This limits what we can infer regarding the mis-
match between timings, but we did also capture information on the first administration of
intervention (relative to induction of the model) and the last administration. Future studies
may use area under the curve approaches to capture response to model induction or drug
intervention, but this was not possible for this large data set. There are tools under develop-
ment for automation of data extraction, which may assist progress in this area [40].
In our meta-analysis, we grouped together the behavioural outcome measures that measure
the same underlying biology. For example, in the case of experiments that reported using the grip
test, 5 studies reported that the test was used to measure grip strength, and 1 reported that the test
was used to measure muscle hypersensitivity [41]. For this reason, in our analysis, we grouped all
grip test outcome measures together as a non–pain-related behavioural outcome measures. It is
possible that the same tests or similar tests could be used and the same measurements reported as
different outcomes; one test may also measure multiple facets of underlying biology. This is one
of the challenges when analysing published data, and principle components analyses of large data
sets such as these may help identify latent domains of behavioural outcome.
We only included studies in which the intervention drug was administered after or at the
same time as the chemotherapeutic agent. Future literature reviews may consider drug inter-
ventions given before chemotherapeutic agents to determine whether prophylaxis can effec-
tively prevent CIPN.
Unfortunately, the reporting of measures to reduce risk of bias was moderate in the studies
included in this systematic review, which limits what we can infer from the results. We hope
this review will highlight this issue in in vivo modelling of CIPN. Systematic review of animal
experiments in other research areas has revealed low reporting of these measures and the nega-
tive impact of failure to report these measures across in vivo domains as diverse as modelling
of stroke, intracerebral haemorrhage, Parkinson disease, multiple sclerosis, and bone cancer
pain [15,29,30,42–44]. This has driven change, influencing the development of reporting
guidelines [45], pain modelling specific guidelines [46], and the editorial policy of Nature Pub-
lishing Group [47]. However, requesting that submitting authors complete a reporting guide-
line without any other intervention is not associated with improved reporting [48]. After an
initial review on the efficacy of interleukin-1 receptor antagonist in animal models of stroke
highlighted low reporting of measures to reduce risk of bias [49], a subsequent review identi-
fied increased reporting of these measures [15], increasing the validity and reliability of these
results. We hope that there will be a similar improvement in studies reporting the use of ani-
mal models of CIPN. We propose that if more studies implement and report measures to
reduce the risk of bias, it will be possible to use a GRADE-type analysis to rate the certainty of
the evidence of animal studies [50]. At present, any such approach is likely to lead to the
majority of evidence being downgraded to the extent that no firm conclusions can be drawn.
The measures to reduce risk of bias that we have assessed are largely derived from what is
known to be important in clinical trials, and the extent to which these measures are important
in animal studies has yet to be fully elucidated. However, reporting of these measures allows
users of research to make informed judgments about the fidelity of the findings presented.
Equally, it may be that there are other measures that are important in animal studies that we
have not considered.
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A recent study from our group has suggested that using SMD estimates of effect sizes with
stratified meta-analysis has a moderate statistical power to detect the effect of a variable of
interest when there are 200 included studies but that the false positive rate is low. This means
that although we may not have sufficient power to detect an effect, we can have confidence
that any significant results observed are likely to be true [51].
Conclusions
This systematic review and meta-analysis provides a comprehensive summary of the in vivo
modelling of CIPN. The data herein can be used to inform robust experimental design of
future studies. We have identified some areas in which the internal and external validity of pre-
clinical CIPN studies may be increased; using both sexes of animals in the modelling of CIPN
and ensuring outcome measures align with those most relevant in the clinic will likely improve
external validity. Measures to reduce risk of bias should be employed to increase the internal
validity of studies. Power analysis calculations illustrate the variation in group size under dif-
ferent conditions and between different behavioural tests and can be used to inform outcome
measure choice in study design.
Materials and methods
This review forms part of a larger review of all in vivo models of painful neuropathy, and the
full protocol is available at www.dcn.ed.ac.uk/camarades/research.html#protocols. Our review
protocol predates the opening of the PROSPERO registry to reviews of in vivo preclinical data.
Methods used were prespecified in the study protocol.
Search strategy
In September 2012, we systematically searched 5 online databases (PubMed, Web of Science,
Biosis Citation Index, Biosis Previews, and Embase) with no language restrictions to identify
publications reporting in vivo modelling of CIPN that reported a pain-related behavioural out-
come measure. The search terms used for each database are detailed in S1 File. Search results
were limited to animal studies using search filters [52,53]. Because we anticipated a high
accrual rate of new publications, we ran an updated search in November 2015 and used
machine learning and text mining to reduce the screening for inclusion workload. This
updated search included 4 online databases (PubMed, Web of Science, Biosis Citation Index,
and Embase) and used an updated animal filter [54]. Biosis Previews was no longer available.
Machine learning and text mining
We used machine learning to facilitate the screening of publications reporting animal models
of CIPN and improve accuracy of the screening process [55]. The screening stage of a system-
atic review involves ‘including’ or ‘excluding’ publications identified in the search based on
their title and abstract, and this was performed by 2 independent reviewers. The publications
from our initial search (with ‘include’/‘exclude’ decisions based on initial dual screening and
differences reconciled by a third reviewer; inter-reviewer agreement Kappa = 0.95, standard
error [SE] = 0.002) were used as a training set for machine learning approaches applied to the
updated search.
Five machine learning groups participated, and 13 classifiers were created and applied to
the updated search (validation set) [16]. We manually screened 10% of the updated publica-
tions (n = 1,188) and used this to assess the performance of these classifiers using measures of
sensitivity, specificity, and precision as described by O’Mara-Eves and colleagues (2015) [56].
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The reconciled decision of the human reviewers was considered the gold standard. We chose
cut-off points such that the sensitivity of each classifier reached 0.95 and measured the result-
ing specificity and precision to choose the classifier that performed best for our data set.
To test the performance of the classifiers in the validation set, we used a random number
generator to select a 10% random sample, and 2 independent investigators checked these for
inclusion or exclusion. From the included studies in the updated search, we used text mining
to identify studies reporting animal models of CIPN by searching for specific chemotherapy
terms within the title and abstract of the identified publications; the inclusion of these studies
was then verified by 2 independent reviewers.
Inclusion and exclusion criteria
We included controlled studies using pain-related behavioural outcome measures that either
characterised models of neuropathy induced by chemotherapeutic agents or tested the effect of
a drug intervention in such models (Fig 2). We required that studies report the number of ani-
mals per group, the mean, and a measure of variance (either the standard error of the mean
[SEM] or the SD).
We excluded studies that administered the drug intervention before model induction,
administered co-treatments, used transgenic models, or used in vitro models.
Measures to reduce risk of bias
We assessed the risk of bias of included studies by recording the reporting of 5 measures to
reduce risk of bias at the study level: blinded assessment of outcome, random allocation to
group, allocation concealment, reporting of animal exclusions, and a sample size calculation
[57].
We also assessed the reporting of a statement of potential conflicts of interest and of com-
pliance with animal welfare regulations [57,58].
Data abstraction
Data were abstracted to the CAMARADES Data Manager (Microsoft Access, Redmond, WA).
For all included studies, we included details of publication (Table 5), animal husbandry,
model, intervention, and other experiment details (Table 6). Outcome data presented graphi-
cally were abstracted using digital ruler software (Universal Desktop Ruler, AVPSoft.com or
Adobe ruler) to determine values. When multiple time points were presented, we abstracted
the time point that showed the greatest difference between model and control groups, or the
greatest difference between treatment and control groups. If the type of variance (e.g., SEM or
SD) was not reported, we characterised the variance as SEM because this is a more conserva-
tive approach in meta-analysis, in which studies are weighted in part by the inverse of the
observed variance. All data were abstracted by 2 independent reviewers.
Data reconciliation
Publication and outcome level data abstracted by 2 independent reviewers were compared,
and any discrepancies were reconciled. For outcome data, SMD effect sizes of individual com-
parisons were calculated for each reviewer’s extracted data, and when these differed by�10%,
they were identified for reconciliation. When individual comparisons differed by<10%, we
took a mean of the 2 effect sizes and of the variance measure.
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Data analysis
We separated the data according to those reporting the modelling of CIPN only and those test-
ing the effect of an intervention in a model of CIPN. We analysed all the behavioural outcome
measures reported. Behavioural outcome measures were separately considered as ‘pain-
related’ or ‘other (non–pain related)’ behavioural outcome measures (Fig 2). This resulted in 4
data sets: (1) animal studies modelling CIPN: pain-related behavioural outcome measures
(data set 1a), (2) animal studies modelling CIPN: other behavioural outcomes (data set 1b), (3)
drug interventions in animal models of CIPN: pain-related behavioural outcome measures
(data set 2a), and (4) drug interventions in animal models of CIPN: other behavioural out-
comes (data set 2b). Data from individual experiments were extracted from each publication,
and these are reported as ‘individual comparisons’.
For each individual comparison, we calculated an SMD effect size. When more than one
relevant behaviour was reported in the same cohort of animals, these individual comparisons
were aggregated (‘nested comparisons’; Fig 2) by behavioural subtype, determined by the site
of stimulus application (e.g., limb or tail) and the modality of the stimulus used (e.g., mechani-
cal or heat). Fixed-effects meta-analysis was used to give a summary estimate of these effects in
each cohort. Cohort-level effect sizes were then pooled using a random-effects meta-analysis
with restricted maximum-likelihood estimation of heterogeneity, in which heterogeneity refers
Table 5. Publication level data abstracted from each publication.
Publication level
Metadata Risk of bias Reporting quality
• First author
• Corresponding author
• Year
• Random allocation
• Allocation concealment
• Blinded assessment
• Sample size calculation
• Animal exclusions
• Compliance with animal welfare regulations
• Statement of potential conflict of interests
https://doi.org/10.1371/journal.pbio.3000243.t005
Table 6. Experiment level data abstracted from each publication.
Experiment level
Animal Husbandry Model Intervention Outcome measure
• Species
• Strain
• Sex
• Supplier
• Country of
supplier
• Type of diet
• Cage rack ventilation
• Type of bedding
• Enrichment
• Habituation time prestudy
• Cage cleaning frequency
• Number per cage
• Shared cages between CIPN and sham
animals
• Number of hours in light cycle
• Room temperature
• Humidity
• Food availability
• Different species housed in same room
• Chemotherapeutic
agent
• Dose
• Number of doses
• Route of
administration
• Model duration
• Weight
• Age
• Time of drug
administration
• Dose
• Route of administration
• Outcome measure type
• Units
• Larger values indicates better/worse
• Number of groups served by control
group
• Time of assessment
• Number of animals per group
• Mean outcome
• Variance
• Number of treatment groups per
control
• Number of animal exclusions and
reason
Abbreviation: CIPN, chemotherapy-induced peripheral neuropathy.
https://doi.org/10.1371/journal.pbio.3000243.t006
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to the variation in study outcomes between studies. When a single control group served multi-
ple comparator (model or treatment) groups, their contribution was adjusted by dividing the
number of animals in the control group by the number of comparator groups served. The Har-
tung and Knapp method was used to adjust test statistics and confidence intervals; this calcu-
lates the confidence intervals using the following formula: effect size + t(0.975,k − 1) × SE.
Results are presented in SMD units along with the 95% confidence intervals.
To provide empirical evidence to inform experimental design and refine modelling of
CIPN, we assessed the extent to which predefined study design and study risk of bias charac-
teristics explained observed heterogeneity. We used stratified meta-analysis for categorical var-
iables and metaregression for continuous variables. The purpose of these subgroup analyses is
to observe whether studies grouped together describing a similar characteristic (e.g., all studies
using male animals versus all studies using female animals) differ in their overall estimates of
effects. Such analyses provide empirical evidence of the impact of study design choices and are
useful to design future experiments. The study design factors assessed using stratified meta-
analysis were animal sex and species, therapeutic intervention, therapeutic intervention dose,
methods to induce the model including the chemotherapeutic agent, and type of outcome
measure. Because drug dose and route of administration are largely important in the context
of the intervention being used, we did not assess the impact of dose or route of administration
across different chemotherapeutic agents or drug interventions. We specified a priori that if
species accounted for a significant proportion of heterogeneity, we would analyse the effect of
study design factors on each species separately. If not, then all data would be analysed together.
We also assessed the impact of reporting of measures to reduce bias. We used metaregression
to assess the impact of time to assessment (defined as the interval between first administration
of chemotherapeutic agent and outcome measurement) and time to intervention administra-
tion (defined as the interval between first administration of chemotherapeutic agent and
administration of intervention). We used a meta-analysis online platform (code available here:
https://github.com/qianyingw/meta-analysis-app) to perform all meta-analyses.
We applied a Bonferroni-Holmes correction for multiple testing that resulted in critical
thresholds for significance as follows: in modelling experiments, p< 0.01 for study design fea-
tures and p< 0.007 for reporting of measures to reduce risk of bias and measures of reporting;
in intervention experiments, p< 0.007 for study design features, and p< 0.007 for reporting
of measures to reduce risk of bias and measures of reporting.
Power analysis of in vivo modelling
To guide sample size estimation for future studies, we performed power calculations for the 6
most frequently reported behavioural tests. To do this, we separately ranked the observed
SMD effect size and the pooled SD and, for each, identified the 20th, 50th, and 80th percentile.
We then used these values to calculate the number of animals required in 9 hypothetical treat-
ment and control groups. Calculations were based on the two-sample two-sided t test, with
80% power and an alpha value of 0.05.
Publication bias
We assessed for potential publication bias by assessing the asymmetry of funnel plots using
visual inspection and Egger’s regression [59]. We assessed for the impact of publication bias
using Duval and Tweedie’s trim and fill analysis [60,61]. We performed these assessments in 4
data sets separately and used individual comparisons rather than summary estimates for each
cohort (Fig 1).
Animal models of chemotherapy-induced peripheral neuropathy
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000243 May 20, 2019 28 / 34
Comparison of intervention efficacy with that observed in human studies
In a clinical systematic review of neuropathic pain [18], selected analgesic agents had been
ranked according to their efficacy, as measured by Number Needed to Treat (NNT) for 50%
pain relief. If preclinical studies included in this review reported use of these agents or their
analogues, we ranked the interventions according to their SMD effect size for attenuation of
pain-related behaviour. We then assessed the correlation between clinical and preclinical rank
using Spearman’s rank correlation coefficient.
Supporting information
S1 Table. Reporting of animal husbandry details. The median habituation time was 7 days
(7–7 IQR). The median number of animals per cage was 4 (2.5–4.5). Reporting of mixed hous-
ing with shams was always ‘Not mixed’. Room temperature 22 ˚C (22 ˚C–23 ˚C IQR). Humid-
ity 55 (53.75–55 IQR).
(DOCX)
S1 Fig. Number of included publications published each year.
(TIF)
S2 Fig. Cumulative meta-analysis of (A) effect sizes and (B) tau2 estimates, ordered by year
of publication.
(TIF)
S3 Fig. Tree plot of prevalence of interventions. A total of 306 different interventions
reported.
(TIF)
S4 Fig. Impact of study design in modelling experiments using other behavioural out-
comes. The size of the squares represents the number of nested comparisons that contribute to
that data point, and the value N represents the number of animals that contribute to that data
point. (A) Outcome measure accounted for a significant proportion of the heterogeneity. (B)
Chemotherapeutic agent accounted for a significant proportion of the heterogeneity. (C)
Strain accounted for a significant proportion of the heterogeneity.
(TIF)
S5 Fig. Effect sizes associated with measures to reduce risk of bias in modelling experi-
ments using other behavioural outcomes.
(TIF)
S6 Fig. Effect sizes associated with reporting of compliance with animal welfare regula-
tions and a statement of potential conflict of interests in modelling experiments using
other behavioural outcomes.
(TIF)
S7 Fig. Modelling experiments using other behavioural outcomes. (A) Visual inspection of
the funnel plot suggests asymmetry. Filled circles represent reported experiments. Solid line
represents global effect size, and dashed line represents adjusted global effect size. (B) Trim
and fill analysis imputed theoretical missing studies (unfilled circles). Filled circles represent
reported experiments. Solid line represents global effect size, and dashed line represents
adjusted global effect size. (C) Egger’s regression was not consistent with small study effects.
(TIF)
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S8 Fig. Impact of study design in intervention experiments using other behavioural out-
comes. The size of the squares represents the number of nested comparisons that contribute to
that data point, and the value N represents the number of animals that contribute to that data
point. (A) Type of outcome measure accounted for a significant proportion of the heterogene-
ity. (B) Strain accounted for a significant proportion of the heterogeneity.
(TIF)
S9 Fig. In intervention experiments using other behavioural outcomes, type of interven-
tion accounted for a significant proportion of the heterogeneity. The size of the squares rep-
resents the number of nested comparisons that contribute to that data point, and the value N
represents the number of animals that contribute to that data point.
(TIF)
S10 Fig. Effect sizes associated with measures to reduce risk of bias in intervention experi-
ments using other behavioural outcomes.
(TIF)
S11 Fig. Effect sizes associated with reporting of compliance with animal welfare regula-
tions and a statement of potential conflict of interests in intervention experiments using
other behavioural outcomes.
(TIF)
S1 File. Terms used in each database for systematic search.
(DOCX)
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